MARK RESTER: Open Payments
NPI 1538140512 · FLOWOOD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,230 in 40 payments from 14 companies in 2025. Trend: 2023 $1,952 · 2024 $1,334 · 2025 $1,230
Food & beverage: $1,230
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 2 | $234 |
| ABBVIE INC. | 13 | $194 |
| Janssen Pharmaceuticals, Inc | 4 | $170 |
| Otsuka America Pharmaceutical, Inc. | 4 | $164 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $105 |
| Supernus Pharmaceuticals, Inc. | 1 | $92 |
| E.R. Squibb & Sons, L.L.C. | 3 | $62 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Tris Pharma Inc | 2 | $42 |
| JAZZ PHARMACEUTICALS INC. | 1 | $36 |
Products named: FANAPT, VRAYLAR, REXULTI, SPRAVATO, LUMRYZ, Qelbree, COBENFY, Auvelity.
Industry payments across MS — which companies pay providers there.
